PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week data from the CASTLE study, in which 74 percent of the 440 patients in the REYATAZ® (atazanavir sulfate)/r arm achieved an undetectable viral load, defined as HIV-1 RNA less than 50 copies/mL, compared with 68 percent of the 443 patients in the lopinavir/r arm. The difference between treatment arms may have been related to the 16 percent discontinuation rate in the REYATAZ/r arm and the 21 percent discontinuation rate in the lopinavir/r arm. These data from the CASTLE study were presented today at the joint 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)/Infectious Diseases Society of America (IDSA) 46th annual conference in Washington, D.C.
